SEC Form 4 · accession 0001567619-19-006231
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Baffi
Officer — EVP, Technical Operations
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 7:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 1, 2019 | A | 11,853 | $0.00 | A | 95,129 | D | |
| Common Stock | Mar 1, 2019 | F | 917 | $94.76 | D | 94,212 | D | |
| Common Stock | holding | — | — | — | 71,882 | I | Shares held by Baffi Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- F2Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements.
- F3Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events.